Linguamatics Automates Critical Insights Discovery in Real-Time with NLP
Linguamatics, a natural language processing (NLP) text analytics provider, has released its I2E AMP platform, which automates the discovery of critical insights from text using NLP.
Linguamatics’ NLP-based text mining is used by commercial, academic, and government organizations, including 18 of the top 20 global pharmaceutical companies, the U.S. Food and Drug Administration (FDA), and U.S. healthcare organizations for knowledge discovery and decision support.
According to the vendor, the I2E Asynchronous Messaging Pipeline (AMP) platform delivers high-throughput, fault-tolerant workflow management for real-time document and record processing, addressing the NLP text-mining and ETL (extract, transform, load) requirements for healthcare and life science organizations by allowing users to plug I2E into enterprise workflows and rapidly process streams of data at scale.
I2E AMP 2.0 includes enhanced functionality to speed overall throughput and performance, sophisticated pre- and post-processing capabilities, a web GUI to simplify the set-up of initial workflows, and new AMP Agents for smarter load balancing, easier deployment, and optimized I2E management.
Going beyond traditional entity mark-up, I2E’s flexible NLP platform provides semantically enriched data that normalizes concepts and relationships based on the relevant context, said David Milward, chief technology officer for Linguamatics. As a result, AMP provides clients with secure, fault-tolerant, scalable, and real-time ETL from unstructured text to structured data.
In addition, said Phil Hastings, chief business development officer for Linguamatics, the 2.0 release includes new options that make it an even more valuable solution that can be applied to multiple use cases across life sciences and healthcare.
Within the life sciences, I2E AMP enables the automated transformation of text into structured data across the drug discovery and development pipeline. I2E AMP is configurable, allowing the flexible use of a range of ontologies and business rules to be applied. According to the company, pharmaceutical companies are using I2E AMP in target selection, for example to generate target-indication dashboards from patents; in business intelligence, to generate email alerts for clinical trial insights; to build safety databases from internal reports; and in regulatory affairs, for document QA.
AMP allows healthcare users to extract critical clinical details buried as unstructured text within EHRs, transform the text into discrete data, populate data warehouses, and support predictive risk models. New pre- and post-processing features enable the identification of document sections and evaluation of I2E NLP results for specific clinical criteria. According to Linguamatics, real-time NLP capability supports a more complete, 360-degree-view of each patient so that providers can more easily detect patient risk and predict adverse events, match patients with clinical trials, or support clinical document improvement workflows.
For more information, visit www.linguamatics.com.